论文部分内容阅读
现已新研制成一种16-苯氧基-ω-四去甲-前列腺素_2-甲基磺胺注射剂(16-Phenoxt-ω-Tetra-nor-PGE-Methylsulfonamide)。可经肌肉或羊膜外注射,终止中期妊娠,其副作用较少。对象为同意流产的16～37岁孕12～20周的70例孕妇,其中70.7％是初产妇。24小时内流产成功率在70％以下。用药量与流产成功率和与副作用有关的发病率成正比。如采用羊膜外注射的方法,用药量控制在50μg以下,对胃肠道的副作用甚微。但如想在24小时内排出宫内容物,使其成功率由27.3％上升到67.7％,就需把药量由25μg 加大到100μg,但同时胃肠
A 16-Phenoxt-ω-Tetra-nor-PGE-Methylsulfonamide has now been newly developed into a 16-phenoxt-ω-tetran-nor-PGE-methylsulfonamide. By intramuscular or amniotic injection, termination of mid-term pregnancy, fewer side effects. The subjects were 70 pregnant women between the ages of 16 and 37 who agreed to miscarriage from 12 to 20 weeks of pregnancy, of which 70.7% were primipara. Abortion within 24 hours success rate below 70%. The dosage is proportional to the success rate of abortion and the incidence of side effects. Such as the use of amniotic injection method, the dosage control in 50μg or less, little side effects on the gastrointestinal tract. But if you want to discharge the contents of the uterus within 24 hours, the success rate increased from 27.3% to 67.7%, the need to increase the dose from 25μg to 100μg, but at the same time gastrointestinal